Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

ia (Ph+ CML) in chronic phase. The effectiveness of Tasigna for this indication is based on major molecular response and cytogenetic response rates at 12 months. The study is ongoing and further data will be required to determine long-term outcome.

Tasigna® (nilotinib) 200 mg capsules is also approved in more than 90 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including Gleevec. The effectiveness of Tasigna for this indication is based on hematologic and cytogenetic response rates.

TASIGNA BOXED WARNING and Additional Important Safety InformationTASIGNA (nilotinib) prolongs the QT interval. Sudden deaths have been reported in patients receiving TASIGNA. TASIGNA should not be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be corrected prior to TASIGNA administration and should be periodically monitored. Drugs known to prolong QT interval and strong CYP3A4 inhibitors should be avoided. Patients should avoid food 2 hours before and 1 hour after taking dose. A dose reduction is recommended in patients with hepatic impairment.

ECGs should be obtained to monitor the QTc at baseline, 7 days after initiation and periodically thereafter, as well as following any dose adjustments.

  • Treatment with TASIGNA can cause Grade 3/4 thrombocytopenia, neutropenia and anemia. Complete blood counts should be performed every 2 weeks for the first 2 months and then monthly thereafter.

  • Caution is recommended in patients with a history of pancreatitis.

  • The use of TASIGNA may result in elevations in bilirubin, AST/ALT and alkaline phosphatase.

  • TASIGNA can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia and hyponatremia (see Boxed WARNING).

  • The concomitant use of strong CYP3A4 inhibitors or anti-arrhythmic drugs (includ
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... July 29, 2014 /PRNewswire-iReach/ -- MHG Medical Management ... launched its Medical Equipment and X-ray Annual ... are tailored to the cruise industry,s unique requirements.  ... operators to propose that they should develop a ... program is intended to create standardized processes and ...
    (Date:7/29/2014)... , July 29, 2014  Instrumentation Laboratory (IL) today announced ... new corporate logo. This is part of a comprehensive rebranding ... Founded in Boston, MA , in 1959, ... companies since 1992.  Other companies in the group include Inova ... Systelab ( Barcelona, Spain ).  Like IL, these ...
    (Date:7/29/2014)... WESTFORD, Mass., July 29, 2014 Cynosure, ... and markets laser- and light-based aesthetic treatment systems for ... months ended June 30, 2014. Second-quarter 2014 financial results ... completed on June 24, 2013. ... revenues increased 45% to $72.6 million , Non-GAAP ...
    Breaking Medicine Technology:MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
    (Date:7/29/2014)... July 29, 2014 DailyGossip.org reveals in its ... by someone who can perfectly understand patients and what they ... , Ellie Gadsby is the author of the new program. ... After years of suffering, Ellie started her very own research. ... remedies. , The author of the Get Rid of Cold ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip reveals ... 5 step holistic system that will permanently eliminate all the ... Coleman his natural treatment will banish symptoms such as mild ... beeping sound heard by patients will be gone forever. , ... 60 days. The author of this program says that at ...
    (Date:7/29/2014)... Daily Gossip indicates in its Natural Vitiligo Treatment ... a popular nutritionist and health specialist. Michael Dawson suffered ... disorder, but none of them worked. , According to ... to look for an alternative vitiligo treatment, which he ... too, to become vitiligo free. , To learn ...
    (Date:7/29/2014)... 2014 (HealthDay News) -- Want young children to embrace ... that,s healthy is good for them. Doing so will ... new study suggests. "Parents and caregivers who are ... better off simply serving the food without saying anything ... food actually is," said study authors Michal Maimaran, of ...
    (Date:7/29/2014)... of severe combat injuries threatening more than one limb, ... record of safety and effectiveness in avoiding amputation, reports ... Plastic and Reconstructive Surgery , the official medical ... (ASPS). , Experience with multiple limb salvage procedures ... success rates, with no increase in complications compared to ...
    Breaking Medicine News(10 mins):Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2
    ... Forest Laboratories, Inc. (NYSE: FRX ) today ... offer by TRC Capital Corporation (TRC) of Toronto, Canada, a ... of the tender offer to purchase up to 3.0 million ... than 1 per cent of its outstanding shares. The ...
    ... KOOL ), a leading supplier of innovative products ... that it will hold a,conference call on Thursday, December 4, ... , The conference call ... Standard Time). The call can be accessed by calling,(800) 860-2422 ...
    ... guidelines, , , WEDNESDAY, Dec. 3 (HealthDay News) -- A ... effective than a diuretic-based strategy in reducing the risk ... high blood pressure, according to a study that included ... Norway, Denmark and Finland. , The patients took either ...
    ... the Baccalaureate Student Population May Signal that Schools Have ... , WASHINGTON, Dec. 3 The American ... survey data showing that enrollment in entry-level baccalaureate nursing ... 2008. Though this marks the eighth consecutive year ...
    ... previously announced, HLTH Corporation (Nasdaq: HLTH ) and its ... will be holding their Annual Meetings of Stockholders beginning at 9:30 ... , A live audio webcast of ... the audio webcast of the meetings, investors can go to ...
    ... Breast-Specific Gamma Imaging (BSGI) is,shown to be ... (hidden) breast cancer. BSGI is a molecular breast ... density and discover very early,stage cancers. According to ... Radiological Society of North America (RSNA) in this ...
    Cached Medicine News:Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 3Health News:ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition 2Health News:Blood Pressure Pill Combo More Effective Than Diuretics 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 2Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 3Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 4Health News:Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN 5Health News:HLTH Corporation and WebMD to Webcast Annual Meetings of Stockholders 2Health News:Molecular Breast Imaging Identifies Occult Cancer 2
    CDIs Ultra-Comfort Bra™ is designed with special single needle stitching that places the cup seams away from critical surgical sites....
    Post-Surgical compression garments...
    Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
    ... The Albumin Cobalt Binding (ACB®) Test ... Ischemia Modified Albumin (IMA®) by measuring the ... patient serum sample. First identified in the ... albumin comes in contact with ischemic tissue ...
    Medicine Products: